GLP-1 Peptide Research Overview¶

Executive Summary¶

Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino acid incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. GLP-1 acts through the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor, to stimulate glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety.

Over the past two decades, GLP-1 receptor agonists have become a cornerstone of metabolic research, with extensive evidence supporting their effects on glycemic control, body weight regulation, and cardiovascular outcomes.

This article provides a comprehensive overview of GLP-1 peptide research, from its discovery to current applications and emerging directions.

Background¶

The discovery of GLP-1 traces back to the observation that oral glucose elicits a greater insulin response than intravenous glucose—a phenomenon termed the "incretin effect." In the 1970s, gastric inhibitory polypeptide (GIP) was identified as the first incretin hormone.

However, it was not until the 1980s that the glucagon-like peptide-1 sequence was identified through molecular cloning and post-translational processing studies of the proglucagon gene.

Researchers discovered that the proglucagon gene is differentially processed in intestinal L-cells to yield GLP-1, whereas in pancreatic alpha cells it produces glucagon.

The active forms of GLP-1, GLP-1(7-36)amide and GLP-1(7-37), were characterized in the early 1990s, and their insulinotropic effects were confirmed in both animal models and human studies. A critical observation was that GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), resulting in a plasma half-life of less than two minutes.

This short half-life presented both a challenge and an opportunity for peptide engineering, ultimately leading to the development of DPP-4-resistant GLP-1 receptor agonists.

Scientific Explanation¶

GLP-1 is encoded by the proglucagon gene (GCG) located on chromosome 2 in humans. Tissue-specific post-translational processing by prohormone convertases determines the final peptide products: in intestinal L-cells, prohormone convertase 1/3 (PC1/3) processes proglucagon to produce GLP-1, GLP-2, and glicentin. The biologically active forms, GLP-1(7-36)amide and GLP-1(7-37), are equipotent at the GLP-1 receptor, though GLP-1(7-36)amide is the predominant circulating form. GLP-1 secretion occurs rapidly following nutrient ingestion, with peak levels reached within 30-60 minutes. Multiple nutrient-sensing pathways are involved, including sweet taste receptors, sodium-glucose cotransporters, and free fatty acid receptors such as GPR119 and GPR120. The secretion profile is biphasic: an early phase driven by neural and hormonal signals, and a sustained phase driven by direct nutrient contact with L-cells in the distal small intestine and colon.

Mechanism¶

GLP-1 exerts its biological effects by binding to the GLP-1 receptor, a seven-transmembrane domain class B G protein-coupled receptor. Upon ligand binding, the receptor undergoes conformational changes that activate intracellular signaling cascades, primarily through the stimulatory G protein (Gαs), leading to adenylyl cyclase activation, cyclic AMP (cAMP) production, and subsequent activation of protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC). In pancreatic beta cells, this signaling cascade potentiates glucose-stimulated insulin secretion through multiple mechanisms: closure of ATP-sensitive potassium channels, increased intracellular calcium mobilization, and enhanced exocytosis of insulin-containing granules. Importantly, the insulinotropic effect of GLP-1 is glucose-dependent—insulin secretion is only potentiated when blood glucose levels are elevated, which reduces the risk of hypoglycemia—a key safety advantage over many other insulin secretagogues. Beyond the pancreas, GLP-1 receptors are expressed in the brain (particularly the hypothalamus and brainstem), gastrointestinal tract, heart, kidneys, and vascular endothelium.

Central GLP-1R activation reduces food intake by promoting satiety and reducing appetite through signaling in the arcuate nucleus, paraventricular nucleus, and area postrema. In the gastric antrum, GLP-1 delays gastric emptying, further attenuating postprandial glycemic excursions.

In extra-pancreatic tissues, GLP-1 signaling exerts anti-inflammatory, cardioprotective, and vasodilatory effects that contribute to its pleiotropic actions.

Research Evidence¶

The research literature on GLP-1 spans multiple decades and includes extensive preclinical and clinical investigations. Drucker's seminal review established the fundamental biology of incretin hormones and their therapeutic potential. Complementary work by Holst characterized the physiological role of GLP-1 in human metabolism, including its effects on gastric emptying, satiety, and glucagon suppression. Clinical translation of GLP-1 research accelerated with the development of DPP-4-resistant analogs. Exenatide, a synthetic version of exendin-4 from Gila monster venom with 53% homology to human GLP-1, received regulatory approval in 2005 as the first GLP-1 receptor agonist. Subsequently, liraglutide (a human GLP-1 analog with a fatty acid side chain enabling once-daily dosing) and semaglutide (optimized for once-weekly administration) advanced the field considerably. Large-scale cardiovascular outcome trials provided robust evidence for semaglutide's effects on cardiovascular risk reduction. The SUSTAIN-6 trial demonstrated that semaglutide reduced the composite cardiovascular endpoint by 26% in patients with type 2 diabetes. The PIONEER program further established the efficacy of oral semaglutide. In obesity research, the STEP trial program showed that semaglutide 2.4 mg once weekly produced mean weight reductions of approximately 15%, representing a transformative advance in obesity pharmacotherapy.

Current Understanding¶

The scientific consensus holds that GLP-1 is a critical integrative regulator of glucose homeostasis, energy balance, and cardiovascular function. The glucose-dependent mechanism of insulin secretion is well-established and distinguishes GLP-1 from sulfonylureas and other insulin secretagogues.

Current research recognizes that GLP-1 receptor signaling extends far beyond the pancreatic beta cell, encompassing central nervous system regulation of appetite, cardiovascular protection, anti-inflammatory effects, and potential benefits in neurodegenerative diseases and non-alcoholic steatohepatitis (NASH).

Nevertheless, important open questions remain. The tissue-specific contributions of GLP-1 signaling to the overall metabolic phenotype are not fully delineated. The role of endogenous GLP-1 in the pathophysiology of type 2 diabetes is debated, as evidence regarding GLP-1 secretion deficits in type 2 diabetes has been inconsistent.

Furthermore, the mechanisms underlying cardiovascular protection—whether direct receptor-mediated effects on cardiac myocytes and vascular endothelium versus indirect effects through weight loss and glycemic improvement—remain an active area of investigation.

Key Research Milestones and Landmark Trials¶

The translation of GLP-1 biology from bench to bedside is marked by several landmark clinical trials.

The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results) demonstrated that liraglutide reduced the risk of major adverse cardiovascular events (MACE) by 13% in patients with type 2 diabetes at high cardiovascular risk, establishing the cardiovascular safety and benefit of GLP-1 receptor agonists.

The SUSTAIN-6 trial followed with semaglutide, showing a 26% reduction in MACE. The REWIND trial extended these findings to dulaglutide, demonstrating cardiovascular benefit in a broader patient population including those without established cardiovascular disease. In the obesity space, the SCALE trial program with liraglutide 3.0 mg established the weight loss efficacy of GLP-1 receptor agonists, while the STEP program with semaglutide 2.4 mg (Wegovy) demonstrated transformative weight loss of approximately 15% at 68 weeks.

The SELECT trial (Semaglutide Effects on cardiovascular Outcomes in People with Overweight or Obesity) extended the evidence beyond diabetes, showing that semaglutide reduced MACE by 20% in individuals with obesity and established cardiovascular disease but without diabetes—a landmark finding that positions GLP-1 receptor agonists as cardiovascular therapies independent of glycemic status.

Emerging research is now focusing on the mechanistic basis for these cardiovascular benefits. Studies employing coronary angiography, cardiac MRI, and endothelial function testing suggest that GLP-1 receptor agonists directly improve vascular function through NO-dependent vasodilation and reductions in vascular inflammation.

Positron emission tomography (PET) imaging with (18)F-FDG has demonstrated reduced arterial wall inflammation in patients treated with semaglutide, providing a direct mechanistic link between GLP-1 signaling and atherosclerotic plaque stabilization.

Future Research¶

Future GLP-1 research is pursuing several promising directions. First, the development of orally bioavailable non-peptide GLP-1 receptor agonists could further expand therapeutic options. Second, combination approaches that co-target GLP-1R with other metabolic receptors—such as the GIP receptor, glucagon receptor, and amylin receptors—represent a major frontier, as exemplified by tirzepatide (GIP/GLP-1 dual agonist) and retatrutide (triple receptor agonist). Third, the exploration of GLP-1 effects in extra-metabolic indications, including neurodegenerative diseases (Parkinson's, Alzheimer's), addiction, inflammatory conditions, and cardiovascular disease independent of diabetes, is generating significant research interest.

Fourth, the molecular pharmacology of biased agonism at the GLP-1 receptor may enable more selective targeting of beneficial signaling pathways while minimizing adverse effects. Finally, personalized approaches based on genetic and metabolic profiling may identify patient subgroups most likely to benefit from specific GLP-1-based interventions.

The role of GLP-1 in hepato-metabolic disease is a particularly active area of investigation. Preclinical studies have demonstrated that GLP-1 receptor agonists reduce hepatic steatosis through both direct effects on hepatocyte lipid metabolism and indirect effects mediated by weight loss and improved insulin sensitivity.

The phase 2b trial of semaglutide in NASH demonstrated significant improvement in NASH resolution without worsening fibrosis compared to placebo, though the primary endpoint of fibrosis improvement was not met.

Current research is investigating whether combination approaches—including GLP-1/GIP dual agonism, GLP-1/glucagon dual agonism, and triple agonists—may achieve superior hepatic outcomes by engaging multiple pathways that coordinately reduce de novo lipogenesis, enhance fatty acid oxidation, and suppress hepatic inflammation.

Frequently Asked Questions¶

What is GLP-1 and where is it produced?

GLP-1 (glucagon-like peptide-1) is a 30/31-amino acid incretin hormone produced primarily by intestinal L-cells in the distal small intestine and colon. It is also produced in the brainstem, where it functions as a neuropeptide regulating appetite and energy balance.

How does GLP-1 stimulate insulin secretion?

GLP-1 binds to the GLP-1 receptor on pancreatic beta cells, activating Gαs-mediated cAMP production. This signaling cascade potentiates glucose-stimulated insulin secretion through PKA and EPAC pathways, enhancing calcium mobilization and insulin granule exocytosis. Crucially, this effect is glucose-dependent.

Why is native GLP-1 not suitable as a therapeutic agent?

Native GLP-1 is rapidly degraded by the enzyme DPP-4, resulting in a plasma half-life of less than 2 minutes. This extremely short half-life renders native GLP-1 impractical for therapeutic use, motivating the development of DPP-4-resistant analogs.

What are the main GLP-1 receptor agonists used in research?

The principal GLP-1 receptor agonists include exenatide (derived from exendin-4), liraglutide (a fatty-acid acylated human GLP-1 analog), and semaglutide (a long-acting analog with once-weekly dosing available in both injectable and oral formulations).

Does GLP-1 affect body weight?

Yes. GLP-1 receptor agonists consistently reduce body weight through central mechanisms promoting satiety and reducing food intake, as well as peripheral effects on gastric emptying and energy expenditure. Semaglutide 2.4 mg produces mean weight reductions of approximately 15% in individuals with obesity.

What cardiovascular effects has GLP-1 research demonstrated?

GLP-1 receptor agonists reduce major adverse cardiovascular events, with semaglutide showing a 26% reduction in the composite cardiovascular endpoint in patients with type 2 diabetes. These effects appear to involve both direct cardioprotective mechanisms and improvements in cardiometabolic risk factors.

What is the role of GLP-1 in non-alcoholic steatohepatitis (NASH)?

Preclinical and clinical studies suggest that GLP-1 receptor agonists reduce hepatic steatosis, inflammation, and fibrosis, making them a subject of active investigation for NASH treatment. Semaglutide has shown beneficial effects on NASH resolution in phase 2 clinical trials.

Are there ongoing research efforts combining GLP-1 with other peptides?

Yes. Multi-receptor agonists combining GLP-1 with GIP, glucagon, and other metabolic peptides represent a major research frontier. Agents such as tirzepatide (GIP/GLP-1 dual agonist) and retatrutide (GIP/GLP-1/glucagon triagonist) demonstrate enhanced metabolic effects compared to GLP-1R agonists alone.

Does GLP-1 have effects in neurodegenerative disease?

Emerging evidence suggests that GLP-1 receptor agonists exert neuroprotective effects through reduced neuroinflammation and improved mitochondrial function. Clinical trials are ongoing in Parkinson's disease and Alzheimer's disease, with early results showing potential cognitive benefits.

What are the limitations of current GLP-1 research?

Current limitations include incomplete understanding of tissue-specific GLP-1 signaling contributions, inconsistent evidence regarding endogenous GLP-1 secretion deficits in type 2 diabetes, gastrointestinal side effects limiting tolerability, and residual uncertainty about long-term effects beyond the 2-5 year trial follow-up windows.

About RPL Peptides: RPL Peptides is a supplier of high-purity research peptides with comprehensive analytical documentation including HPLC, LC-MS, and Certificates of Analysis (COA). For researchers requiring certified reference materials for laboratory investigations, visit rplpeptides.com or explore detailed molecular data at the RPL Peptides Data Center.

References¶

Cell Metabolism

The Lancet

Gastroenterology

Physiological Reviews

Diabetes, Obesity and Metabolism

New England Journal of Medicine

The Lancet Diabetes & Endocrinology